Cullinan Therapeutics to Present First Data for CLN-619, a Novel Anti-MICA/B Antibody, in ... : vimarsana.com

Preliminary data from CLN-619 in combination with checkpoint inhibitor pembrolizumab show objective responses in patients with tumor types that are typically unresponsive to pembrolizumab, such as non-small cell lung cancer

Related Keywords

Cambridge , Cambridgeshire , United Kingdom , United States , Virginia , Chad , American , Jeff Jones , Rose Weldon , Jeffrey Jones , Alexander Spira , Linkedin , Development Plan , American Society Of Clinical Oncology , Exchange Commission , Cullinan Therapeutics Inc , Virginia Cancer Specialists Research Institute , Nasdaq , Clinical Oncology , Annual Meeting , Key Clinical Results , Combination Arm , Combination Cohorts , Updated Key Clinical Results , Chief Medical Officer , Olive Investor , Investor Event , Cullinan Therapeutics , Chad Messer , Private Securities Litigation Reform Act , Annual Report ,